Release date: 2014-10-29
The World Health Organization (WHO) recently announced that by the end of 2015, it plans to produce two experimental doses of two experimental Ebola vaccines.
At the WHO meeting in Geneva, the end of June, hundreds of thousands of doses of vaccine will be used to help infected countries. Vaccine producers, senior government representatives, and other groups come together to discuss time and programs for planned clinical trials, as well as support and funding for group immunization programs.
Marie-paulkieny, WHO's Assistant Director-General for Health Systems and Innovation, said that the two-stage trial of the two vaccine candidates has begun, and the other five Ebola vaccines will begin trials in 2015. The WHO expects that since October 19, the Ebola virus has infected nearly 10,000 people in Sierra Leone, Liberia and Guinea, and about half of them have died. Since some cases are not recorded, the real number may be higher. The epidemic is still spreading, and an effective vaccine will be the key to changing the rules of the game.
These two vaccines that will increase production have been tested early in healthy subjects. One is a chimpanzee adenovirus vaccine containing a superficial Ebola protein developed by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. It is currently being tested in the United States, the United Kingdom and Mali.
The other is a recombinant vesicular stomatitis virus (rvsv) vaccine developed by the Health Canada and newlink gene companies. It is currently being tested in the United States and plans to start testing in Europe and Africa. The third candidate vaccine is a combination of two vaccines: one developed by Johnson & Johnson and the National Institute of Allergy and Infectious Diseases, and the other by the Danish biotechnology company, bavariannordic. It will begin the i-term trial in the US and Europe in January next year.
It is reported that in December, the ii and iii trials to test the effectiveness and safety of the first vaccine mentioned above will be conducted in Liberia, and will be tested in Sierra Leone in January next year. The current plan is to test both GlaxoSmithKline and Newlink's vaccines, but the plan will change based on data from ongoing i-term trials. Kiyny said that in April next year, the ii and iii trials are expected to receive data.
Group immunization is usually only implemented after the accumulation of complete safety and efficacy data. Therefore, the timeline for the proposed Ebola vaccine development is unprecedented. Now, who is considering how to better engage with the community to prepare for the Ebola vaccination.
Source: Chinese Journal of Science
YT-60
YT-60
Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwinsz.com